Elicio is a Boston-based, clinical-stage biotechnology company building an off-the-shelf cancer vaccine against the mutated KRAS driver mutation, and it now stands at the single most important fork in its corporate history. The randomized Phase 2 AMPLIFY-7P trial in resected pancreatic ductal adenocarcinoma missed its pre-specified disease-free survival endpoint in the intent-to-treat population, a result that erased roughly two-thirds of the equity value between March and September of this year.
The stock trades near $2.35 on a share count near 26 million. That pairing sets the net asset floor the market is implicitly pricing, and it frames the distance between the equity and the cash it actually holds. The implied market cap sits near $62 million against a cash balance of $23.5 million at mid-year, a pairing that defines the asset base a buyer is effectively paying for. A board-related note of $10 million sits alongside that cash on the balance sheet.
The counter-narrative is real but narrower than the miss implies. Post-hoc analysis in the completely resected, R0 subgroup showed a hazard ratio of 0.65, and the biomarker relationship between mutant KRAS specific T cell response and outcome held at a hazard ratio of 0.22. Management has redrawn the Phase 3 plan around the R0 population with additional dosing, and the July financing extends the runway into the first quarter of next year. The equity is now a priced-in bet on whether a subgroup signal from a failed primary endpoint survives scrutiny at registrational scale, funded with a cash balance that covers only one binary event.